Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996675 | 0.85 | BCL9 (0.41) | BCL9CTNNB1CES2CES1KMT2A | |
| SCHEMBL1999176 | 0.80 | KMT2A (0.45) | CES2CES1KMT2AKDM4EMEN1 | |
| SCHEMBL2000685 | 0.79 | ALOX15 (0.41) | BCL9CTNNB1CES2CES1KMT2A | |
| SCHEMBL5324362 | 0.76 | MAOB (0.52) | BCL9CTNNB1KMT2AKDM4EMAOB | |
| SCHEMBL30100005 | 0.75 | CES2 (0.45) | CES2CES1KMT2AKDM4EMEN1 | |
| SCHEMBL1994064 | 0.74 | ALOX15 (0.49) | BCL9CTNNB1CES2CES1KMT2A | |
| SCHEMBL1401783 | 0.74 | ALDH1A1 (0.48) | BCL9CTNNB1CES2CES1KMT2A | |
| SCHEMBL1993937 | 0.74 | KMT2A (0.43) | BCL9CTNNB1CES2CES1KMT2A | |
| SCHEMBL28499259 | 0.73 | CES2 (0.48) | BCL9CTNNB1CES2CES1KDM4E | |
| SCHEMBL9079554 | 0.73 | ALDH1A1 (0.41) | BCL9CTNNB1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429411-B2 | Chroman compound, liquid crystal composition including the compound and liquid crystal display element including the liquid crystal composition | CHISSO PETROCHEMICAL CORPORATION (JP) | 2008-09-30 | — | — | US | disclosed |
| EP-1491612-B1 | Chroman compound, liquid crystal composition including the compound and liquid crystal display element including the liquid crystal composition | CHISSO PETROCHEMICAL CORP (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20050247910-A1 | Chroman compound, liquid crystal composition including the compound and liquid crystal display element including the liquid crystal composition | JNC PETROCHEMICAL CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050247910-A1 | Chroman compound, liquid crystal composition including the compound and liquid crystal display element including the liquid crystal composition | RB1, RCC1, CDYL | BCL9 220/4885CTNNB1 1099/4885CES2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.